Arrowhead Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 12, 2025 and accepted by EDGAR at May 12, 2025, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $542.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-10-01 to 2025-03-31 | $545.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $381.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-10-01 to 2025-03-31 | $219.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-31 | $21.6m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-10-01 to 2025-03-31 | $43.3m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-10-01 to 2025-03-31 | $1.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $370.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-10-01 to 2025-03-31 | $197.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $2.75 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-10-01 to 2025-03-31 | $1.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $2.78 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-10-01 to 2025-03-31 | $1.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 134,484,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-10-01 to 2025-03-31 | 130,265,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-10-01 to 2025-03-31 | $313.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-10-01 to 2025-03-31 | $12.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2025-03-31 | $1.14bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $1.57bn | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $220.5m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2025-03-31 | $683.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-024666. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.